ArticleCancer discovery2020
HER2-Mediated Internalization of Cytotoxic Agents in
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06278870 (Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial), which is not on this map. Cited by 173 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 4 pooled it
12.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial
Who cites it
173 citing papers in PubMed, 4 syntheses or guidelines pooled it, 279 citations in OpenAlex.
- Evaluating the efficacy and safety of antibody-drug conjugates in non-small cell lung cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Antibody-drug conjugates in HER2-positive advanced or metastatic gastric cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.JNCI cancer spectrum · 2024Pooled it
- Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis.Frontiers in oncology · 2022Pooled it
- Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Clinical lung cancer · 2026Trial
- NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Breast cancer research : BCR · 2024Trial
- Trastuzumab Deruxtecan in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.Nature medicine · 2023Trial
- Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.JCO precision oncology · 2022Trial
- Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.BMC medicine · 2022Trial
- Trastuzumab Deruxtecan inThe New England journal of medicine · 2022Trial
- Antibody-drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges.Cancer chemotherapy and pharmacology · 2026Review
- HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies.Cancer discovery · 2026Article
- Preclinical in vitro and in vivo activity of trastuzumab deruxtecan againstGynecologic oncology reports · 2026Article
- Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers.Cell reports. Medicine · 2026Article
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.JTO clinical and research reports · 2026Article
- HER2 Alterations in Squamous Cell Lung Cancer: Biology, Therapeutic Landscape, and Emerging Precision Approaches.Cancers · 2026Review
- Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
49 authors at 7 institutions in 4 countries.
Bob T Li *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.ORCID https://orcid.org/0000-0001-6661-8733
Flavia Michelini *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.
Sandra Misale *Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.
Emiliano CoccoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Laura BaldinoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yanyan CaiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sophie ShifmanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Hai-Yan TuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-7125-9878
Mackenzie L MyersDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Chongrui XuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-3474-2809
Marissa MattarMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Inna KhodosMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Megan LittleMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Besnik QeriqiMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Gregory WeitsmanRichard Dimbleby Department of Cancer Research, King's College London, London, United Kingdom.
Clare J WilhemDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0003-2437-5387
Alshad S LalaniPuma Biotechnology, Los Angeles, California.
Irmina DialaPuma Biotechnology, Los Angeles, California.
Rachel A FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID https://orcid.org/0000-0003-2263-5413
David B SolitDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul R BarberRichard Dimbleby Department of Cancer Research, King's College London, London, United Kingdom.
Tony NgRichard Dimbleby Department of Cancer Research, King's College London, London, United Kingdom.
Michael OffinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-7959-3018
James M IsbellWeill Cornell Medical College, New York, New York.
David R JonesWeill Cornell Medical College, New York, New York.
Helena A YuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Sheeno ThyparambilmProbe Inc., Rockville, Maryland.
Wei-Li LiaomProbe Inc., Rockville, Maryland.
Anuja BhalkikarmProbe Inc., Rockville, Maryland.
Fabiola CecchiAstraZeneca, Gaithersburg, Maryland.
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason S LewisWeill Cornell Medical College, New York, New York.ORCID https://orcid.org/0000-0001-7065-4534
Darren J BuonocoreDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Alan L HoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Vicky MakkerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pedram RazaviDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Maria E ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark G KrisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
John T PoirierDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-9795-5644
Ronglai ShenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Junji TsurutaniAdvanced Cancer Translational Research Institute, Department of Medical Oncology, Showa University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6260-6943
Gary A UlanerWeill Cornell Medical College, New York, New York.
Elisa de StanchinaMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Neal RosenMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-8307-654X
Charles M RudinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-5204-3465
Maurizio ScaltritiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org lib1@mskcc.org michelif@mskcc.org misales@mskcc.org.ORCID https://orcid.org/0000-0002-5522-1447
Memorial Sloan Kettering Cancer Center · USBreast Cancer Now · GBMicroprobes (United States) · USDana-Farber Cancer Institute · USPuma Biotechnology (United States) · USAstraZeneca (Japan) · JPShowa University · JP
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2007 to 2026
$31.2MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MBRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MCancer Research UK 16463NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA190642NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA234361NCI NIH HHS T32 CA160001NIH HHS U54 OD020355
Abstract
Amplification of and oncogenic mutations in
Indexed as
AdultAgedAged, 80 and overCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansLung NeoplasmsMaleMiddle AgedMutationERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06278870ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.